RETRACTED ARTICLE: Neuroprotective effects of ellagic acid on cuprizone-induced acute demyelination through limitation of microgliosis, adjustment of CXCL12/IL-17/IL-11 axis and restriction of mature oligodendrocytes apoptosis
Open Access
- 1 January 2017
- journal article
- retracted article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 55 (1) , 1679-1687
Abstract
Context: Ellagic acid (EA) is a natural phenol antioxidant with various therapeutic activities. However, the efficacy of EA has not been examined in neuropathologic conditions. Objective: In vivo neuroprotective effects of EA on cuprizone (cup)-induced demyelination were evaluated. Material and methods: C57BL/6 J mice were fed with chow containing 0.2% cup for 4 weeks to induce oligodendrocytes (OLGs) depletion predominantly in the corpus callosum (CC). EA was administered at different doses (40 or 80 mg/kg body weight/day/i.p.) from the first day of cup diet. Oligodendrocytes apoptosis [TUNEL assay and myelin oligodendrocyte glycoprotein (MOG+)/caspase-3+ cells), gliosis (H&E staining, glial fibrillary acidic protein (GFAP+) and macrophage-3 (Mac-3+) cells) and inflammatory markers (interleukin 17 (IL-17), interleukin 11 (IL-11) and stromal cell-derived factor 1 α (SDF-1α) or CXCL12] during cup intoxication were examined. Results: High dose of EA (EA-80) increased mature oligodendrocytes population (MOG+ cells, p < 0.001), and decreased apoptosis (p < 0.05) compared with the cup mice. Treatment with both EA doses did not show any considerable effects on the expression of CXCL12, but significantly down-regulated the expression of IL-17 and up-regulated the expression of IL-11 in mRNA levels compared with the cup mice. Only treatment with EA-80 significantly decreased the population of active macrophage (MAC-3+ cells, p < 0.001) but not reactive astrocytes (GFAP+ cells) compared with the cup mice. Discussion and conclusion: In this model, EA-80 effectively reduces lesions via reduction of neuroinflammation and toxic effects of cup on mature OLGs. EA is a suitable therapeutic agent for moderate brain damage in neurodegenerative diseases such as multiple sclerosis.Keywords
Funding Information
- Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences
- Tehran University of Medical Sciences
- Tehran University of Medical Sciences and Health Services
This publication has 61 references indexed in Scilit:
- Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNSActa Neuropathologica, 2012
- Astrogliosis During Acute and Chronic Cuprizone Demyelination and Implications for RemyelinationASN Neuro, 2012
- IL-17-Induced Act1-Mediated Signaling Is Critical for Cuprizone-Induced DemyelinationJournal of Neuroscience, 2012
- Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced DemyelinationJournal of Molecular Neuroscience, 2012
- CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivoaxial diffusivityJournal of Neuroinflammation, 2011
- Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damageProstaglandins, Leukotrienes and Essential Fatty Acids, 2011
- CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelinationProceedings of the National Academy of Sciences, 2010
- Antioxidant Therapies for Traumatic Brain InjuryNeurotherapeutics, 2010
- HIV‐1‐infected and/or immune activated macrophages regulate astrocyte SDF‐1 production through IL‐1βGlia, 2006
- GenePattern 2.0Nature Genetics, 2006